• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

强脉冲光疗法抑制睑板腺炎症:睑板腺分泌物的非靶向代谢组学分析。

Intense Pulsed Light Therapy to Inhibit Meibomian Gland Inflammation: Untargeted Metabolomics Analysis of Meibomian Gland Secretions.

机构信息

Department of Ophthalmology, Joint Shantou International Eye Center, Shantou University and the Chinese University of Hong Kong, Shantou, Guangdong, China.

出版信息

Photobiomodul Photomed Laser Surg. 2022 Oct;40(10):715-727. doi: 10.1089/photob.2022.0058.

DOI:10.1089/photob.2022.0058
PMID:36286576
Abstract

To assess the inhibitory effects of intense pulsed light (IPL) on meibomian gland (MG) inflammation. IPL treatment is effective for dry eye disease (DED) caused by meibomian gland dysfunction (MGD). However, the anti-inflammatory and regeneration stimulating effects of IPL on MGD remain unclear. Moreover, studies on inflammatory metabolites in MG secretions are lacking. Six patients with DED were administered two IPL treatments. Ocular surface disease index (OSDI) questionnaires were used to assess DED, MGD signs, including degree of obstruction, secretion, and atrophy of the MG, tear film break-up time (TBUT) was assessed before and after treatments. To determine IPL treatment-induced changes in metabolites, liquid chromatography tandem mass spectrometry (LC-MS/MS) was used to analyze MG secretions. Data were gathered before the first treatment (time A) and 2 weeks after the second treatment (time B). Average OSDI score showed a significant decrease (time A and B measurements were 44.07 and 16.65, respectively). Besides, statistically significant differences were observed in MG signs before and after treatments: degree of obstruction improved and secretions became thinner. TBUT was significantly increased to the normal range. LC-MS/MS led to the identification of 53 differential metabolites: 23 were upregulated (e.g., estradiol, coenzyme Q, and azelaic acid) and 30 were downregulated (e.g., prostaglandins, 20-hydroxyeicosatetraenoic acid, and arachidonic acid). Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis showed that most differential metabolites were involved in steroid hormone biosynthesis. Periorbital IPL treatment can improve chronic inflammation of the MG and promote its normal secretion. The steroid hormone biosynthetic pathways may be activated to participate in this anti-inflammatory effect.

摘要

评估强脉冲光 (IPL) 对睑板腺 (MG) 炎症的抑制作用。 IPL 治疗对睑板腺功能障碍 (MGD) 引起的干眼症 (DED) 有效。然而,IPL 对 MGD 的抗炎和再生刺激作用尚不清楚。此外,关于 MG 分泌物中炎症代谢物的研究还很少。 六例 DED 患者接受了两次 IPL 治疗。使用眼表疾病指数 (OSDI) 问卷评估 DED、MGD 体征,包括阻塞程度、分泌物和 MG 萎缩,在治疗前后评估泪膜破裂时间 (TBUT)。为了确定 IPL 治疗引起的代谢物变化,使用液相色谱串联质谱 (LC-MS/MS) 分析 MG 分泌物。数据在第一次治疗前 (时间 A) 和第二次治疗后 2 周 (时间 B) 收集。平均 OSDI 评分显著降低(时间 A 和 B 的测量值分别为 44.07 和 16.65)。此外,MG 体征在治疗前后有统计学差异:阻塞程度改善,分泌物变薄。TBUT 显著增加到正常范围。LC-MS/MS 鉴定出 53 种差异代谢物:23 种上调(如雌二醇、辅酶 Q 和壬二酸),30 种下调(如前列腺素、20-羟二十碳四烯酸和花生四烯酸)。京都基因与基因组百科全书途径富集分析显示,大多数差异代谢物参与甾体激素生物合成。眶周 IPL 治疗可改善 MG 的慢性炎症,促进其正常分泌。甾体激素生物合成途径可能被激活以参与这种抗炎作用。

相似文献

1
Intense Pulsed Light Therapy to Inhibit Meibomian Gland Inflammation: Untargeted Metabolomics Analysis of Meibomian Gland Secretions.强脉冲光疗法抑制睑板腺炎症:睑板腺分泌物的非靶向代谢组学分析。
Photobiomodul Photomed Laser Surg. 2022 Oct;40(10):715-727. doi: 10.1089/photob.2022.0058.
2
A Retrospective Study of Treatment Outcomes and Prognostic Factors of Intense Pulsed Light Therapy Combined With Meibomian Gland Expression in Patients With Meibomian Gland Dysfunction.强脉冲光联合睑板腺按摩治疗睑板腺功能障碍的疗效观察及预后因素分析
Eye Contact Lens. 2021 Jan 1;47(1):38-44. doi: 10.1097/ICL.0000000000000704.
3
Efficacy of intense pulsed light therapy on signs and symptoms of dry eye disease: A meta-analysis and systematic review.强脉冲光疗法治疗干眼疾病的体征和症状的疗效:Meta 分析和系统评价。
Indian J Ophthalmol. 2023 Apr;71(4):1316-1325. doi: 10.4103/IJO.IJO_2987_22.
4
Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction.强脉冲光(IPL)疗法治疗睑板腺功能障碍。
Cochrane Database Syst Rev. 2020 Mar 18;3(3):CD013559. doi: 10.1002/14651858.CD013559.
5
Comparison of two intense pulsed light patterns for treating patients with meibomian gland dysfunction.比较两种强脉冲光模式治疗睑板腺功能障碍患者的疗效。
Int Ophthalmol. 2020 Jul;40(7):1695-1705. doi: 10.1007/s10792-020-01337-0. Epub 2020 Mar 21.
6
The Approach of Intense Pulsed Light Treatment in Patients with Different Severities of Meibomian Gland Dysfunction.强脉冲光治疗不同严重程度睑板腺功能障碍患者的方法。
Curr Eye Res. 2023 Mar;48(3):231-237. doi: 10.1080/02713683.2022.2147955. Epub 2022 Nov 21.
7
Effect of Intense Pulsed Light Therapy in Dry Eye Disease Caused by Meibomian Gland Dysfunction: A Systematic Review and Meta-Analysis.强脉冲光疗法治疗睑板腺功能障碍引起的干眼的疗效:系统评价和荟萃分析。
Eye Contact Lens. 2022 Oct 1;48(10):424-429. doi: 10.1097/ICL.0000000000000934. Epub 2022 Sep 5.
8
Comparative Evaluation in Intense Pulsed Light Therapy Combined with or without Meibomian Gland Expression for the Treatment of Meibomian Gland Dysfunction.强脉冲光治疗联合或不联合睑板腺按摩治疗睑板腺功能障碍的疗效比较。
Curr Eye Res. 2021 Aug;46(8):1125-1131. doi: 10.1080/02713683.2020.1867750. Epub 2021 Jan 18.
9
The Efficacy of Intense Pulsed Light Combined With Meibomian Gland Expression for the Treatment of Dry Eye Disease Due to Meibomian Gland Dysfunction: A Multicenter, Randomized Controlled Trial.强脉冲光联合睑板腺按摩治疗睑板腺功能障碍相关性干眼的疗效:一项多中心、随机对照研究。
Eye Contact Lens. 2021 Jan 1;47(1):45-53. doi: 10.1097/ICL.0000000000000711.
10
Meibum Expressibility Improvement as a Therapeutic Target of Intense Pulsed Light Treatment in Meibomian Gland Dysfunction and Its Association with Tear Inflammatory Cytokines.强脉冲光治疗睑板腺功能障碍中改善睑脂排出作为治疗靶点及其与泪液炎症细胞因子的相关性。
Sci Rep. 2019 May 21;9(1):7648. doi: 10.1038/s41598-019-44000-0.

引用本文的文献

1
Dry Eye Disease Management Via Technological Methods: A Systematic Review and Network Meta-analysis.通过技术方法管理干眼疾病:一项系统评价和网状Meta分析
Ophthalmol Ther. 2025 Jul 2. doi: 10.1007/s40123-025-01187-y.